This is a prospective, open-label, single arm, multicenter clinical study to evaluate the
safety, tolerability, efficacy in combination with tislelizumab and mitoxantrone
hydrochloride liposome combination treatment in patients with relapsed or refractory
Extranodal Natural Killer/T Cell Lymphoma（NKTCL）
This is a prospective, open-label, single arm, multicenter clinical study to explore the
maximum tolerated dose (MTD) of liposomal mitoxantrone hydrochloride when combined with
tislelizumab in patients with relapsed or refractory Extranodal Natural Killer/T Cell
Lymphoma（NKTCL）. Liposomal mitoxantrone hydrochloride will be given on day 1 at two different
doses (16 mg/m2, 20 mg/m2) and be combined with tislelizumab. The dose limited toxicity (DLT)
will be evaluated after the first cycle of therapy. A maximum of 6 cycles of therapy are
planned. An dose expansion study of mitoxanquinone hydrochloride liposome at recommended
phaseII dose (RP2D) dose level combined with tirelizumab was conducted to explore the
efficacy and safety tolerance of the combined regimen. After 6 cycles of induction therapy,
if the outcome was assessed as complete remission (CR)/partial remission (PR)/Stable disease
(SD), continued maintenance therapy with tirelizumab.
Extranodal Natural Killer T Cell Lymphoma
Tislelizumab combined with Liposomal mitoxantrone hydrochloride,
Maintenance of tislelizumab
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.